Your browser is old and is not supported. Upgrade for better security.
Wefunder logo

Invest in Hera Diagnostics

Hera Diagnostics saves lives by delivering cervical cancer screening to the global community

$36,945

reserved of a $50,000 goal
INVESTMENT TERMS
$13.9M valuation cap Convertible Note
$250, $500, $1K, $10K
LEAD INVESTOR
Encore Health
Encore Health is proud to collaborate with Hera Diagnostics, sharing the same vision of developing cost effective technology that revolutionizes cancer screening procedures, for the sake of improving health. We also share with Hera the social commitment to contribute to the medical community, providing practical solutions that facilitate the prevention and care of cancerous diseases.We´re excited to start this new project with a company like Hera Diagnostics and with its team of valuable professionals, whose experience and trajectory as developers of cervical cancer screening technology can lead us to find new devices and ways to detect and treat cancer at early stages, thus allowing a healthier society worldwide.

Encore Health is convinced that this collaboration and partnership will take us all even further in our projects and goals as a main player in medical science, ensuring success of all involved.
Pitch Video
Investor Panel

Highlights

1
Over 300,000 women die annually from cervical cancer even though the disease is easily treatable
2
90% of cervical cancer deaths occur in underserved populations globally
3
Hera will reduce those deaths by delivering high-tech screening to low-tech communities
4
Our device is portable, accurate, affordable, painless and gives real time, point-of-care results
5
Phase 1 begins 2021: Mexico then Chile, Peru, Colombia, Brazil, Argentina, Bolivia, China, India
6
Projected annual revenues exceed $100M in our phase 1 markets alone
7
Hygienic protective sleeves generate attractive recurring revenue streams for each deployed device
8
Team is composed of talented women, LatinX technologists and proven company builders.

Our Team

Cervical cancer is a leading cause of death from cancer among women in developing countries. Hera Diagnostics technology was developed to address this crisis through reliable, affordable and immediate screening technology.

Pitch

Overview